Park Medi World Shares Hit 10% Upper Circuit Despite Market Selloff; Emkay Initiates ‘Buy’, Sees 35% Upside
New Delhi [India], June 19: Healthcare stock Park Medi World bucked the broader market weakness on Friday, rallying 10 per cent after brokerage firm Emkay Research initiated coverage with a ‘Buy’ rating and a target price of ₹350 per share, indicating a potential upside of around 35 per cent from current levels.
The stock closed at ₹278.25 apiece on the BSE after attracting strong buying interest even as benchmark equity indices remained under pressure.
Emkay Research believes Park Medi World is well positioned to benefit from India’s expanding healthcare sector, citing the company’s scalable business model, efficient asset utilisation and disciplined expansion strategy. The brokerage expects the hospital chain to deliver sustained earnings growth, supported by rising occupancy levels, improved operational efficiencies and an expanding network.
The brokerage has assigned a target price of ₹350 per share, implying nearly 35 per cent upside from the stock’s prevailing market price.
Park Medi World has been expanding aggressively through both greenfield and acquisition-led strategies. Earlier this year, the company strengthened its footprint by increasing hospital capacity and expanding into new markets, positioning itself to capitalise on growing demand for quality healthcare services.
The company had also reported strong financial performance in the March quarter, with healthy growth in revenue, profitability and operating margins, supported by higher bed capacity and improved operating leverage.
The latest rally comes after an already impressive run in the stock. Park Medi World has delivered robust gains since its market debut, supported by consistent earnings growth, expansion initiatives and improving investor sentiment towards the healthcare sector. Friday’s surge further reinforced the stock’s momentum despite the broader market witnessing heavy selling pressure.
Disclaimer: This article is for informational purposes only and does not constitute financial advice.
